Amantadine in a multimodal analgesic regimen for alleviation of refractory osteoarthritis pain in dogs

B. D.X. Lascelles, J. S. Gaynor, E. S. Smith, S. C. Roe, Denis J Marcellin-Little, G. Davidson, E. Boland, J. Carr

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) do not always provide sufficient pain relief in dogs with osteoarthritis (OA). Hypothesis: The use of amantadine in addition to NSAID therapy will provide improved pain relief when compared with the use of nonsteroidal analgesics alone in naturally occurring OA in dogs. Animals: Thirty-one client-owned dogs with pelvic limb lameness despite the administration of an NSAID. Methods: The study was randomized, blinded, and placebo controlled with parallel groups (days 21-42). On day 0, analgesic medications were discontinued. On day 7, all dogs received meloxicam for 5 weeks. On day 21, all dogs received amantadine (3-5mg/kg once daily per os) or placebo for 21 days, in addition to receiving meloxicam. Assessments were performed before the study and on days 7, 21, and 42. Primary outcome measures were blinded owner assessments of activity using client-specific outcome measures (CSOM) on days 0, 7, 21, and 42. Data were analyzed by a mixed model approach. Results: For CSOM activity, there was a significant time by treatment effect (P = .009). On the basis of the planned post hoc Mests of postrandomization means, there was a significant difference between treatment groups on day 42 (P = .030), with the amantadine group being more active. Conclusions and Clinical Importance: In dogs with osteoarthritic pain refractory to an NSAID, physical activity is improved by the addition of amantadine. Amantadine might be a useful adjunct therapy for the clinical management of canine osteoarthritic pain.

Original languageEnglish (US)
Pages (from-to)53-59
Number of pages7
JournalJournal of Veterinary Internal Medicine
Volume22
Issue number1
DOIs
StatePublished - Jan 1 2008
Externally publishedYes

Fingerprint

Amantadine
Intractable Pain
osteoarthritis
analgesics
Osteoarthritis
Analgesics
pain
meloxicam
Dogs
nonsteroidal anti-inflammatory agents
dogs
Anti-Inflammatory Agents
Outcome Assessment (Health Care)
Pain
analgesia
drug therapy
placebos
Placebos
Pharmaceutical Preparations
Canidae

Keywords

  • Dog
  • Nonsteroidal anti-inflammatory
  • Owner
  • Pain
  • Subjective assessment

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Amantadine in a multimodal analgesic regimen for alleviation of refractory osteoarthritis pain in dogs. / Lascelles, B. D.X.; Gaynor, J. S.; Smith, E. S.; Roe, S. C.; Marcellin-Little, Denis J; Davidson, G.; Boland, E.; Carr, J.

In: Journal of Veterinary Internal Medicine, Vol. 22, No. 1, 01.01.2008, p. 53-59.

Research output: Contribution to journalArticle

Lascelles, B. D.X. ; Gaynor, J. S. ; Smith, E. S. ; Roe, S. C. ; Marcellin-Little, Denis J ; Davidson, G. ; Boland, E. ; Carr, J. / Amantadine in a multimodal analgesic regimen for alleviation of refractory osteoarthritis pain in dogs. In: Journal of Veterinary Internal Medicine. 2008 ; Vol. 22, No. 1. pp. 53-59.
@article{c38f878b8950423094c25564e76bb578,
title = "Amantadine in a multimodal analgesic regimen for alleviation of refractory osteoarthritis pain in dogs",
abstract = "Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) do not always provide sufficient pain relief in dogs with osteoarthritis (OA). Hypothesis: The use of amantadine in addition to NSAID therapy will provide improved pain relief when compared with the use of nonsteroidal analgesics alone in naturally occurring OA in dogs. Animals: Thirty-one client-owned dogs with pelvic limb lameness despite the administration of an NSAID. Methods: The study was randomized, blinded, and placebo controlled with parallel groups (days 21-42). On day 0, analgesic medications were discontinued. On day 7, all dogs received meloxicam for 5 weeks. On day 21, all dogs received amantadine (3-5mg/kg once daily per os) or placebo for 21 days, in addition to receiving meloxicam. Assessments were performed before the study and on days 7, 21, and 42. Primary outcome measures were blinded owner assessments of activity using client-specific outcome measures (CSOM) on days 0, 7, 21, and 42. Data were analyzed by a mixed model approach. Results: For CSOM activity, there was a significant time by treatment effect (P = .009). On the basis of the planned post hoc Mests of postrandomization means, there was a significant difference between treatment groups on day 42 (P = .030), with the amantadine group being more active. Conclusions and Clinical Importance: In dogs with osteoarthritic pain refractory to an NSAID, physical activity is improved by the addition of amantadine. Amantadine might be a useful adjunct therapy for the clinical management of canine osteoarthritic pain.",
keywords = "Dog, Nonsteroidal anti-inflammatory, Owner, Pain, Subjective assessment",
author = "Lascelles, {B. D.X.} and Gaynor, {J. S.} and Smith, {E. S.} and Roe, {S. C.} and Marcellin-Little, {Denis J} and G. Davidson and E. Boland and J. Carr",
year = "2008",
month = "1",
day = "1",
doi = "10.1111/j.1939-1676.2007.0014.x",
language = "English (US)",
volume = "22",
pages = "53--59",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Amantadine in a multimodal analgesic regimen for alleviation of refractory osteoarthritis pain in dogs

AU - Lascelles, B. D.X.

AU - Gaynor, J. S.

AU - Smith, E. S.

AU - Roe, S. C.

AU - Marcellin-Little, Denis J

AU - Davidson, G.

AU - Boland, E.

AU - Carr, J.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) do not always provide sufficient pain relief in dogs with osteoarthritis (OA). Hypothesis: The use of amantadine in addition to NSAID therapy will provide improved pain relief when compared with the use of nonsteroidal analgesics alone in naturally occurring OA in dogs. Animals: Thirty-one client-owned dogs with pelvic limb lameness despite the administration of an NSAID. Methods: The study was randomized, blinded, and placebo controlled with parallel groups (days 21-42). On day 0, analgesic medications were discontinued. On day 7, all dogs received meloxicam for 5 weeks. On day 21, all dogs received amantadine (3-5mg/kg once daily per os) or placebo for 21 days, in addition to receiving meloxicam. Assessments were performed before the study and on days 7, 21, and 42. Primary outcome measures were blinded owner assessments of activity using client-specific outcome measures (CSOM) on days 0, 7, 21, and 42. Data were analyzed by a mixed model approach. Results: For CSOM activity, there was a significant time by treatment effect (P = .009). On the basis of the planned post hoc Mests of postrandomization means, there was a significant difference between treatment groups on day 42 (P = .030), with the amantadine group being more active. Conclusions and Clinical Importance: In dogs with osteoarthritic pain refractory to an NSAID, physical activity is improved by the addition of amantadine. Amantadine might be a useful adjunct therapy for the clinical management of canine osteoarthritic pain.

AB - Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) do not always provide sufficient pain relief in dogs with osteoarthritis (OA). Hypothesis: The use of amantadine in addition to NSAID therapy will provide improved pain relief when compared with the use of nonsteroidal analgesics alone in naturally occurring OA in dogs. Animals: Thirty-one client-owned dogs with pelvic limb lameness despite the administration of an NSAID. Methods: The study was randomized, blinded, and placebo controlled with parallel groups (days 21-42). On day 0, analgesic medications were discontinued. On day 7, all dogs received meloxicam for 5 weeks. On day 21, all dogs received amantadine (3-5mg/kg once daily per os) or placebo for 21 days, in addition to receiving meloxicam. Assessments were performed before the study and on days 7, 21, and 42. Primary outcome measures were blinded owner assessments of activity using client-specific outcome measures (CSOM) on days 0, 7, 21, and 42. Data were analyzed by a mixed model approach. Results: For CSOM activity, there was a significant time by treatment effect (P = .009). On the basis of the planned post hoc Mests of postrandomization means, there was a significant difference between treatment groups on day 42 (P = .030), with the amantadine group being more active. Conclusions and Clinical Importance: In dogs with osteoarthritic pain refractory to an NSAID, physical activity is improved by the addition of amantadine. Amantadine might be a useful adjunct therapy for the clinical management of canine osteoarthritic pain.

KW - Dog

KW - Nonsteroidal anti-inflammatory

KW - Owner

KW - Pain

KW - Subjective assessment

UR - http://www.scopus.com/inward/record.url?scp=40549119855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40549119855&partnerID=8YFLogxK

U2 - 10.1111/j.1939-1676.2007.0014.x

DO - 10.1111/j.1939-1676.2007.0014.x

M3 - Article

VL - 22

SP - 53

EP - 59

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 1

ER -